TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06250777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan
Description: Chemotherapy : Every 3weeks as below until withdrawal of patient consent, progression, death or loss to follow-up:~- Trastuzumab Deruxtecan (T-DXd) 5.4mg/kg
Study: NCT04813640

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Novel spectacles for myopia control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Novel spectacles for myopia control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacles
Description: Novel spectacles for myopia control

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Spectacles
Description: Novel spectacles for myopia control
Study: NCT06378931

Intervention type: OTHER
Intervention: Quality of life progression after parathyroidectomy
Description: Study the progression of quality of life.
Study: NCT06024317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Knowledge Intervention
Description: Counseling scripts assessing and addressing vaccination-related knowledge gaps

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Knowledge Intervention
Description: Counseling scripts assessing and addressing vaccination-related knowledge gaps
Study: NCT05600972

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FSH priming
Description: Patients who are randomized into the FSH priming arm will receive two days of FSH injections of 150 IU/day. Oocyte retrieval will be scheduled at 42 hours after the last FSH injection.
Study: NCT05217680

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Administration of monthly intravitreal bevacizumab (4-12 injections)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lucentis®
Description: Administration of monthly intravitreal ranibizumab (4-12 injections)
Study: NCT05342584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax Oral Tablet
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV
Study: NCT05640713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ThisCART19A
Description: ThisCART19A is a new type CAR-T therapy for patients with r/r B Cell Malignancy .

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Pill
Description: Fludarabine is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is used for lymphodepletion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16 Protocol
Description: VP-16 is used for lymphodepletion.
Study: NCT05768217

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Community Resiliency Collective Efficacy Intervention (CRCEI)
Description: The Community Resiliency Collective Efficacy Intervention (CRCEI) will involve community members in dialogue on thriving, community leadership, and organizing for social change. Participants in the intervention condition will be asked to participate in 2 sessions of discussions about community thriving and a 7-week training program on the following topics: Building on the Strengths of Your Community, Collective Efficacy and its Effects on Violence Prevention \& Community Mental Health, Non-threatening Peaceful Intervention Principles and Strategies: Part One, Non-threatening Peaceful Intervention Principles and Strategies: Part Two, Safety and Roles of Police and Community in Intervening, Active/Effective listening and non-violent communication skills, and Community Resources and Indirect Intervention.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education Sessions
Description: Comparison neighborhoods will receive health education sessions across a variety of community-identified health topics as a control intervention. (9 sessions)
Study: NCT05054062

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel node mapping using MRI
Description: Sentinel lymph node mapping in melanoma patients using a magnetic tracer and MRI
Study: NCT06279819

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: gut microbiota-targeted dietary intervention
Description: The dietary intervention used the dietary intervention plan constructed in Phase 2, on the basis of which each study participant's individual dietary habits, food preferences and economic level were taken into account.~The dietary intervention was delivered by sending fresh ingredients. To ensure the freshness and quality of the ingredients, 2 dedicated researchers were jointly responsible for the procurement of fresh ingredients, which were purchased through regular channels on Monday, Wednesday and Friday mornings.~Ingredients will be delivered three times a week for a 12-week intervention period. The initial food items to be sent include: 90g of fish rich in omega-3 fatty acids; 300g of vegetables and/or legumes, and 200g of fruits; 30g of nuts; and a cup of probiotic yogurt.~Guided dietary follow-up was conducted through video viewing and WeChat or telephone follow-up. The researcher will provide cooking instruction or dietary pattern guidance by sending videos every two weeks.
Study: NCT05289830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Participants will receive Escitalopram 2 weeks: 10 mg/day (1 capsule) 8 weeks: 20 mg/day (2 capsules) 2 weeks: 10 mg/day (1 capsule)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo supplements 2 weeks: 1 capsule 8 weeks: 2 capsules 2 weeks: 1 capsule
Study: NCT05337657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB491+Letrozole
Description: Drug：The dose of GB491 is 150 mg, which should be taken with a meal and taken twice daily at approximately the same time each day, approximately 12 hours apart
Study: NCT06359782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Esterase Inhibitor Injection [Cinryze]
Description: C1 Esterase Inhibitor Injection \[Cinryze\]

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium Chloride /physiological saline (0.9%) in equal volume dosed intravenous
Study: NCT06451354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided erector spinae plane block after spinal anesthesia and at the end of surgery. The erector spinae plane block will be performed by using bupivacaine 0.25% (20 ml in each side). Erector spinae plane block will be performed at the level of T9.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Quadratus lumborum plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided quadratus lumborum plane block after spinal anesthesia at the end of surgery. The quadratus lumborum plane block will be performed by using bupivacaine 0.25% (20 ml in each side).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lateral Transversus abdominis plane block (20 ml bupivacaine 0.25% in each side)
Description: Patients will receive bilateral ultrasound-guided transversus abdominis plane block after spinal anesthesia at the end of surgery. The transversus abdominis plane block will be performed by using bupivacaine 0.25% (20 ml in each side) to the lateral abdominal wall in the mid-axillary line, between the lower costal margin and iliac crest.
Study: NCT06029972

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tilpisertib Fosmecarbil
Description: Tablets administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets administered orally
Study: NCT06518928

Intervention type: OTHER
Intervention: Artificial Intelligence assisted sperm selection
Description: SiD software for sperm selection
Study: NCT04738942

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300 mg, IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab
Description: Vedolizumab 300 mg, IV infusion
Study: NCT05078957

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool samples will be collected from participants at baseline and annually during 5 years

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool samples will be collected from participants at baseline and annually during 5 years

Intervention type: OTHER
Intervention: Stool sampling
Description: Stool samples will be collected from participants at baseline and annually during 5 years

Intervention type: OTHER
Intervention: Frailty phenotype
Description: According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.

Intervention type: OTHER
Intervention: Frailty phenotype
Description: According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.

Intervention type: OTHER
Intervention: Frailty phenotype
Description: According to Fried frailty phenotype based on the assessment of 5 criteria: shrinking (unintentional weight loss), weakness (grip strength), poor endurance (exhaustion), slowness (walking speed) and physical activity. Frail phenotype is defined as the presence of at least 3 criteria of the above mentioned and Pre-frail phenotype as the presence of 1 or 2 criteria.

Intervention type: OTHER
Intervention: Blood plasma collection
Description: Blood plasma collection to measure persistent inflammation and immune activation

Intervention type: OTHER
Intervention: Blood plasma collection
Description: Blood plasma collection to measure persistent inflammation and immune activation

Intervention type: OTHER
Intervention: Blood plasma collection
Description: Blood plasma collection to measure persistent inflammation and immune activation
Study: NCT05840302

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activity monitor
Description: Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activity monitor
Description: Measure of number of steps and physical activity during one week using the activity monitor (connected watch) named the ActiGraph-wGT3X-BT medical device, Pre-test before intervention, post-test 3-months and 1-year after intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Self and hetero assessments measuring pain, different determinants of chronic pain and physical activity
Study: NCT04444895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanadelumab
Description: Lanadelumab SC injection
Study: NCT04948788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 ；YY-20394
Description: SHR1459 plus YY-20394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR1459 ；YY-20394
Description: SHR1459 plus YY-20394

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine-Oxaliplatin
Description: Gemcitabine-Oxaliplatin
Study: NCT05847855

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for fragmentomic profiles of plasma cell-free DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for fragmentomic profiles of plasma cell-free DNA

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood collection
Description: Blood collection for fragmentomic profiles of plasma cell-free DNA
Study: NCT06556628

Intervention type: DEVICE
Intervention: Increased Body Temperatures
Description: Collecting data on patients whose body temperatures increase due to fighting an illness.
Study: NCT06181578

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ganglionated plexus ablation
Description: This intervention involves the targeted ablation of ganglionated plexus sites, specifically focusing on the left superior ganglionated plexus (LSGP), left inferior ganglionated plexus (LIGP), right anterior ganglionated plexus (RAGP), and right inferior ganglionated plexus (RIGP).
Study: NCT06209931

Intervention type: PROCEDURE
Intervention: RIRS
Description: RIRS with tip flexible pressure-controlling ureteral access sheath versus mini PCNL for the treatment of 2-3-cm kidney stones
Study: NCT06024317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Reminders
Description: Reminders of upcoming vaccination due dates, sent to the mother's mobile phone
Study: NCT05159284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone Ophthalmic
Description: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop, for a total of 14 days of treatment. Repeat on day 28: 1 drop 4 times daily for 12 days, followed by twice daily for 2 days and stop. Patients in the intervention arm will receive two 14-day cycles of hydrocortisone.

Intervention type: DEVICE
Group type: OTHER
Intervention: MGD Rx EyeBag® eyelid warming device
Description: Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGD Rx EyeBag® eyelid warming device
Description: Eyelid warming device used once daily for 10 minutes followed by lid massage for 12 weeks by patients in both control and intervention arm.
Study: NCT06024317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Reminders
Description: Reminders of upcoming vaccination due dates, sent to the mother's mobile phone

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Incentives
Description: Conditional incentives for timely vaccination, tailored to each child's vaccination schedule

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Incentives
Description: Conditional incentives for timely vaccination, tailored to each child's vaccination schedule
Study: NCT05159284

Intervention type: DEVICE
Group type: OTHER
Intervention: Lephanet® lid wipes
Description: Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lephanet® lid wipes
Description: Lid hygiene with Lephanet® lid wipes used twice daily for 3 weeks followed by once daily for 9 more weeks by patients in both control and intervention arm.

Intervention type: DEVICE
Group type: OTHER
Intervention: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%
Description: Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
Study: NCT06024317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati - Service notifications
Description: Service notifications (e.g., related to stockouts or service non-availability), sent to the mother's mobile phone
Study: NCT05159284

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thealoz Duo® artificial tear with trehalose 3% and sodium hyaluronate 0.15%
Description: Artificial tear supplementation with Thealoz Duo® 4 times daily for 12 weeks by patients in both control and intervention arm.
Study: NCT05511194

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced Recovery After Surgery therapeutic protocol
Description: Feeding and early ambulation, double short IV antibiotic regimen.

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional management
Description: Delayed feeding and ambulation, triple short IV antibiotic regimen.
Study: NCT05447325

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (generic themes then flavor-specific themes)
Description: Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive generic/regular PSAs that address vaping harms more broadly; during the second six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (flavor-specific themes then generic themes)
Description: Messages are in the format of public service announcement (PSA) images that contain both textual (1-2 brief sentences) and illustrative visual components. The messages are designed to educate the participants about the harms and costs associated with e-cigarette use (e.g., negative health consequences, undesirable social perceptions, etc.). Half of the messages focus specifically on the harms and costs associated with using flavored vape products, while the other half address vaping harms broadly (i.e., not specifically focus on those related to flavored vaping). Participants in this arm will receive anti-vaping messages through emails and text messages every week. Specifically, over the course of a year, during the first six months, they will receive flavor-specific PSAs that address vaping harms specifically associated with the use of flavored vape products; during the second six months, they will receive generic/regular PSAs that address vaping harms more broadly.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to Anti-Vaping Messages (no message exposure)
Description: Participants will not receive any message intervention in this arm.
Study: NCT05903235

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality-based Mirror Therapy (VR+MT)
Description: In this VR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb simultaneously while observing the animated hand as mirroring reflection of the affected hand within the immersive environment, which presented on the goggle via the VR+MT system.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed Reality-based Mirror Therapy (MR+MT)
Description: In the MR+MT group, the patients will be instructed to perform the unilateral movements of the non-affected upper limb concurrently meanwhile watching the real-time mirroring image reflection of the non-affected upper limb's movements of the patients captured, transformed, and superimposed on the affected upper limb, which projected to the screen from the front side via the MR+MT system.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Mirror Therapy (MT)
Description: In the traditional MT group, patients will be instructed to perform the unilateral movements of the non-affected upper limb at the same time while watching the mirror of a mirror box placed in front of the patient's midsagittal plane, in which the illusory reflection of the non-affected upper limb appears as if it were the another affected upper limb.
Study: NCT05312866

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard analgesia (paracetamol +fentanyl)
Description: Patients will receive standard analgesia (paracetamol 15mg/kg plus fentanyl 1ug/kg) iv

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrolaminar block with bupivacaine + magnesium sulfate + dexamethasone
Description: Patients will receive intraopertative retrolaminar block: 15 ml of bupivacaine 0. 25 % plus 2ml magnesium sulfate 10% (200mg) plus 2ml (8mg) dexamethasone on each side by slipping the needle of injection on the bone of spinous process and lamina.
Study: NCT05723991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Disitamab Vedotin and Gemcitabine
Description: Disitamab Vedotin (RC48) 2.0mg/kg, once every two weeks, intravenous drip (60-90 min); Gemcitabine is 1000mg/m2, once every two weeks. After completing 3 cycles of neoadjuvant combined therapy, imaging evaluation was performed. If the tumor is T0, radical surgery for bladder cancer was performed; Otherwise, perform radical surgery for bladder cancer after completing 1-3 cycles of treatment (total cystectomy+standard/extended lymph node dissection)
Study: NCT04854993

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex 6 mg/kg
Description: i.v. injection of an increased (by 50%) dose of sugammadex to reverse dNMB

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex 4 mg/kg
Description: i.v. injection of a standard dose of sugammadex to reverse dNMB
Study: NCT04993131

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver transplant
Description: Liver transplant.
Study: NCT06105879

Intervention type: DEVICE
Intervention: covered or open skin
Description: transcutaneous mesarument of covered or open skin area

Intervention type: DEVICE
Intervention: covered or open skin
Description: transcutaneous mesarument of covered or open skin area

Intervention type: DEVICE
Intervention: covered or open skin
Description: transcutaneous mesarument of covered or open skin area
Study: NCT01003561

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: spinal anesthesia for surgery
Description: spinal anesthesia (T10) for elective TURP surgery
Study: NCT04917744

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Ancillary studies

Intervention type: OTHER
Intervention: Medical Chart Review
Description: Review of medical charts